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Main conclusions and options for mitigation 
  This is the first documented outbreak of Zika virus (ZIKAV) infection in French Polynesia and New Caledonia. 
  During the course of the ZIKAV outbreak, neurological and auto-immune complications have been reported 
in a context of concurrent circulation of two dengue serotypes (dengue 1 and 3) since February 2013. 
  Vigilance must be enhanced towards imported cases of ZIKAV infection in the EU Member States and EU 
overseas countries and territories and outermost regions, in particular where effective vectors are present; 
early detection of cases is essential to reduce the risk of autochthonous transmission. 
  Clinicians and travel medicine clinics should be aware of the situation in the Pacific islands and include 
ZIKAV infection in their differential diagnosis. An isolated positive result for dengue IgM antibodies among 
travellers returning from areas affected by Zika should prompt a possible investigation for another flavivirus 
aetiology.  
  The potential neurological and auto-immune complications might require specific healthcare capabilities and 
treatment (ICU) which need to be taken into account in an insular context facing a large-scale Zika 
outbreak.  
  As an emerging pathogen, the laboratory capacity to confirm suspected Zika cases should be strengthened 
in the region as well as in Europe to differentiate ZIKAV infections from other arboviral dengue-like 
illnesses. Regional reference laboratories could provide support to confirm suspect cases.  
  As many unanswered questions remain, further epidemiological and laboratory investigations could be 
conducted to establish: 
−  evidence about eco-epidemiology of ZIKAV (viral strain genetic characteristics, transmission cycle(s), 
vectors and reservoir hosts) to assess its implications for public health; 
−  the relationship between neurological and auto-immune complications and ZIKAV infection, notably 
with other aetiologies, previous infection with other infectious agents and human risk factors;  
−  the performance of Zika serology and its cross-reactivity with other flaviviral infections; 
−  the possibility of using urine samples for detection of the ZIKAV genome as well as other flaviviral 
infections.  
  Blood safety authorities need to be vigilant regarding the epidemiological situation and should consider 
deferral of donors with travel history in line with measures defined for West Nile virus. Blood safety 
procedures are already in place in the Pacific region in the context of the ongoing outbreak of dengue and 
chikungunya and have included ZIKAV nucleic acid testing since early January 2014 in French Polynesia.  
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Source and date of request 
ECDC internal decision, 24 January 2014. 
Public health issue 
This document assesses the risk associated with the outbreak of Zika virus infections, considered as an emerging 
disease, to public health in the EU/EEA and the risk to EU/EEA citizens in order to anticipate future developments. 
The aim of this risk assessment is to summarise all available evidence on Zika virus epidemiology and disease 
presentation, and to assess the current outbreak of Zika in French Polynesia in view of this information, including 
the possible association with neurological and autoimmune complications. 
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  As exposure to infected mosquitoes is likely to be the principal risk for infection, prevention of ZIKAV 
infection is based on protection against mosquito bites and vector control; these have to be customised 
according to the potential vector species actually present in the area. 
  Onward transmission in the EU from imported cases during the winter season is not to be expected, but 
vigilance during the mosquito season is required in areas where a potential vector is present. Indeed the 
possibility of autochthonous transmission of tropical mosquito-transmitted viruses in continental Europe 
does exist.  
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Disease background information 
Zika is a mosquito-borne viral disease caused by Zika virus (ZIKAV), a flavivirus from the Flaviviridae family [1].  
Clinical presentation 
The clinical signs of Zika disease include acute onset of fever, non-purulent conjunctivitis, headache, arthralgia, 
myalgia, asthenia, rash (in general maculo-papular) and, less frequently, retro-orbital pain, anorexia, vomiting, 
diarrhoea and abdominal pain. In the literature, Zika is described as a mild, self-limiting febrile illness lasting 4–7 
days without severe complications, no fatalities and a low hospitalisation rate [2-4].  
It should be noted that the description of the clinical presentation is based on a limited number of case reports and 
outbreak investigations: Uganda (1962, one case), laboratory-acquired infection (1973, one case), Indonesia (1977 
and  1978,  seven  cases),  Yap,  Federated  States  of  Micronesia  (2007,  31  cases),  Senegal  (2009,  two  cases), 
Cambodia (2010, one case), Thailand (2013, two cases) and Indonesia (2013, one case) and recently travellers 
returning from French Polynesia to Japan and New Caledonia [3,5-12]. Current treatment guidance is based on a 
limited body of evidence. There is no vaccine. During the outbreak on Yap, the local State Department of Health 
Services recommended symptomatic treatment based on acetaminophen (paracetamol) for fever and pain and 
antihistamines for pruritic rash. Treatment with acetylsalicylic acid and  no-steroid anti-inflammatory drugs was 
discouraged because of the increased risk of haemorrhagic syndrome reported with other flaviviruses [13].  
The 2007 Zika outbreak on Yap Island in the Federated States of Micronesia is so far the only well documented 
and investigated large outbreak. Based on the case definition ‘acute onset of generalized macular or papular rash, 
arthritis or arthralgia, or non-purulent conjunctivitis’, 185 cases of suspected Zika disease were identified. Of the 
suspected cases, 49 (26%) were classified as laboratory-confirmed and 59 as probable cases. These cases had 
onset between early April and mid-July 2007 (13 consecutive weeks), the median age was 36 years and 61% were 
female. Clinical characteristics were documented for 31 confirmed cases and included: macular or papular rash 
(frequency 90%, median duration of 6 days ranging from 2 to 14 days), fever either subjective  or measured 
(frequency 65%), arthritis or arthralgia (frequency 65%, median of duration of 3.5 days ranging 1 to 14 days), 
non-purulent  conjunctivitis  (frequency  55%),  myalgia  and  headache  (both  around  45%  frequency)  and  retro-
orbital pain (frequency 39%). 
Rash was not reported for the seven cases in Indonesia in 1977–78  but was present  in a Canadian traveller 
returning from Thailand in January 2013. In addition, three travellers returning from French Polynesia in 2013 
confirmed with ZIKAV infection presented with a similar clinical profile mainly including fever, rash and headaches 
[9-12]. This investigation also provided an estimate that 18% of the infected residents of Yap island had a clinical 
illness  probably  attributable  to  Zika  virus,  even  though  the  number  of  infected  people  is  difficult  to  estimate 
because of cross-reactivity with other flaviviruses [3,14]. 
A recent case report about two cases imported to Japan from French Polynesia mentions leucopenia and moderate 
thrombocytopenia for both cases, and the same findings were reported for the recent confirmed Zika case in a 
Canadian traveller returning from Thailand [4, 5]. The latter biological feature was not previously reported in the 
scientific literature. 
Because of the overlapping symptoms, clinical diagnosis of Zika remains a challenge in tropical settings, particularly 
in areas with simultaneous transmission of dengue and chikungunya viruses. The Zika IgM antibody assay might be 
affected by a high degree of serologic cross-reactivity with other flaviviruses, as observed during the 2007 Yap 
outbreak  in  patients  previously  exposed  to  dengue  virus  type  1  in  2004  [15].  Additional  estimations  of  key 
epidemiological  parameters  need  to  be  established  for  Zika  on  clinical  presentation  and  biological  parameter 
anomalies.  
Disease distribution and phylogeny 
The first virus isolation was performed in April 1947 from a symptomatic sentinel rhesus monkey in a Yellow fever 
study in the Zika forest, close to Entebbe [16].  
The knowledge of the geographical range of the ZIKAV is coming from the below mentioned case reports, outbreak 
investigations and serological evidence of infection. Serological and entomological studies reported the circulation 
of the virus in tropical areas of western Africa such as Nigeria in Oyo state (1971), Sierra Leone (1972), Ivory 
Coast (1999), Cameroon (2009), Senegal (1993 and 2011) and of central Africa in Gabon (1975, 2007–2010), 
Uganda (1969–1970), Central African Republic (1979) [17–24].  
Zika viruses were isolated in Malaysia (1969), Pakistan (1983), Cambodia (2010), Thailand (2013), Indonesia (in 
1981 and more recently one case report documenting a ZIKAV infection among a 52-year-old Australian woman 
returning  from  the  Jakarta  area  in  2013)  [2,3,7,9,10,12,14,25,26].  Prior  to  the  current  outbreak  in  French 
Polynesia, the only Zika outbreak that had been identified in the Pacific region was on Yap, Federated States of 
Micronesia, in 2007, as described above.  
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The  first  full-length  sequencing  of  the  genome  of ZIKAV performed  in  2006  reports single-strand  positive  RNA 
consisting of 10 794 nucleotides with the Open Reading Frame of 3 419 amino acids encoding structural genes and 
five non-structural genes [27].  
ZIKAV is related to Spondweni virus, a virus identified in South Africa that causes dengue-like illness in humans. 
Comprehensive  genomic  comparison  showed  different  sub-clades  reflecting  the  existence  of  two  main  virus 
lineages  (African and Asian) [14,28]. Additional  phylogenetic  analysis confirmed the two  geographically  distinct 
lineages of ZIKAV (African and Asian) with a circulation of the virus in South-east Asia for at least the past 50 years 
[29]. The Yap Island outbreak is assuredly linked with the introduction of a South-east Asian ZIKAV strain(s) and 
the paediatric cases of ZIKAV infection in Cambodia (2010). A recent study of the molecular evolution of ZIKAV in 
Africa described the historical diffusion pattern of ZIKAV in Africa with two sub-lineages in West and East Africa. 
This  study  highlights  several  recombination  events  considered  uncommon  among  flaviviruses ,  and retrace  its 
probable introduction in Asia (Malaysia) [23].  
Eco-epidemiology 
In East Africa, ZIKAV is most probably maintained in a sylvatic cycle with cyclic epizooty involving non-human 
primates and mosquitoes (Aedes spp.) in tropical forest [20,30-32].  
In West Africa and Asia (South-east Asia), serological surveys indicate a likely silent circulation and antibodies have 
been detected in various animals including large mammals such as orang-utans, zebra, elephants, water buffalo 
and rodents [25,29,33]. The virus was isolated in Senegal monkeys (Cercopithecus aethiops and Erythrocebus 
patas) [29].  
The expansion of outbreaks without monkeys supports the role of humans as an amplifying host as seen with 
other arboviral diseases. As many unanswered questions remain, each new emergence is of high interest for in-
depth  assessment  of  the  eco-epidemiology  of  Zika,  its  transmission  cycle(s)  including  principal  and  secondary 
vectors,  mammal  and  non-mammal  reservoir  hosts  and  specific  transmission  modalities  (including  non-vector-
borne). This information is considered to be key for proper preparedness and response to outbreaks. 
Entomological aspect 
Historically, the virus was later isolated from Aedes africanus mosquitoes and the vector transmission was 
experimentally established using Aedes aegypti mosquitoes between an infected mouse and a monkey in 1956 [16, 
17]. Between 1961 and 1963, new investigations in the Zika forest found the virus in Aedes africanus collected in 
the canopy [18]. 
Two aedine mosquito species of public health importance are present in the Pacific, Aedes aegypti, the major 
vector of dengue in the region and Aedes polynesiensis, the major vector of filariasis and vector of dengue. They 
are spread across all islands of French Polynesia [34]. 
Aedes aegypti mosquitoes infected with Zika virus have been found in the wild [26,35,36]. The vector competence 
of the local population is currently tested in the ‘Institut Louis Malarde’ in Tahiti. Preliminary results support the 
role of Ae. aegypti as a vector of ZIKAV. Ae. aegypti present in French Polynesia is the domestic form, spread 
throughout most of the tropical and subtropical regions of the world through trade. It is a diurnal feeder breeding 
in artificial containers. Adult mosquitoes are sensitive to temperature and humidity. It is probable that Ae. aegypti 
is the main vector in this outbreak as it is a susceptible vector and capable of transmitting ZIKAV [34].  
The capability of Ae. polynesiensis to transmit ZIKAV (vector competence) is currently being tested and preliminary 
results support a probable role for this species as a vector of ZIKAV. Confirmation of these results is in process. Ae. 
polynesiensis has been dispersed rather widely by man in the eastern part of the Pacific region, possibly from 
Samoa. It is a semi-domestic salt-tolerant species with an extremely wide range of breeding habitats such as tree 
holes, coconut shells and husks, crab holes, artificial containers of various types, and even small water bodies on 
the ground. It is frequently found in canoes [37]. Aedes polynesiensis females bite humans mainly during the day.  
Aedes aegypti is widespread in the South Pacific including New Caledonia [38,39]. Aedes polynesiensis is present 
from French Polynesia up to the Fiji islands but is absent from the western islands such as New Caledonia [37-39]. 
Aedes albopictus has already been proven to become infectious through experimental infection with ZIKAV [40] 
and has been found infected in the wild in Gabon [24]. This vector is present in the western part of the South 
Pacific region (Papua New Guinea, Solomon Islands, Fiji, and Tonga), probably present in Vanuatu, and absent 
from New Caledonia and French Polynesia. It was not detected during entomological surveys in the Cook Islands or 
on the Wallis and Futuna Islands in 2007 [41]. 
Finally, Aedes hensilli has a limited spatial distribution (Yap, Palau, Chuuk) [39]. Because of its abundance among 
the mosquitoes captured on the island, it was suspected to be a vector of ZIKAV during the 2007 outbreak in Yap. 
However, no ZIKAV infection was detected in the mosquitoes captured during this outbreak [3].  
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Laboratory diagnosis 
Zika diagnosis is primarily based on detection of viral RNA from clinical specimens. The viraemic period has not 
been established but is believed to be short, allowing for direct virus detection during the first 3–5 days after onset 
of symptoms [1,14]. Specific assays have been published for Asian and African ZIKAV strains targeting the 
envelope gene or NS5 region, the latter being highly conserved among flaviviruses compared to envelope genes 
[1,14,42]. PCR assays for dengue would not detect the Zika viral genome. Pan-flavivirus assays and subsequent 
sequencing analysis can be used as an alternative screening test for possible ZIKAV infection [43,44]. Virus 
isolation is carried out for research purposes. The use of urine as a specimen for viral genome detection by RT-PCR 
might be the laboratory diagnostic method of choice since the disappearance of the genome in serum has been 
shown for yellow fever, dengue, West Nile virus and Zika [11,45-47].  
Dengue NS1 antigen assays (Elisa, Rapid-test) are believed to be specific to dengue virus, and negative dengue 
NS1 assays should trigger testing for other flaviruses in a patient with a dengue-like symptomatology.  
ZIKAV-specific IgM/IgG antibodies can be detected by Elisa and immunofluorescence assays in serum specimens 
from day 5–6 of illness. Detection of an increase of antibodies in a pair of sera is recommended. IgM antibody 
response in primary flavivirus/ZIKAV-infected patients has been reported specific for ZIKAV with minor cross-
reactivity with heterologous flaviviruses [14]. Positive results should be confirmed by neutralisation assay (i.e. 
Plaque Reduction Neutralisation Test (PRNT)) to document at least a fourfold increase of ZIKAV neutralising 
antibody titres [13]. However, in some patients with a probable previous history of flavivirus infection, a fourfold 
increase of neutralising antibodies to other flaviviruses has been observed [14]. There are no commercial 
serological assays available for detection of Zika-specific antibodies to our knowledge. 
A recent Zika case reported by Germany in a traveller returning from Thailand exemplified the challenge to 
diagnose ZIKAV infection. The patient was examined ten days after the onset of dengue-like symptoms with a 
rash. The dengue serology was positive for IgM antibodies against dengue, both indirect immunofluorescence 
assay and rapid test (SD BIOLINE Dengue Duo NS1 Ag + Ab Combo), and negative for dengue IgG antibodies and 
dengue NS1 antigen (tested by ELISA and rapid test). Results of indirect immunofluorescence assay on specimens 
taken one month after onset gave positive results for IgG and IgM antibodies against ZIKAV, indicating an acute or 
recent ZIKAV infection but cross reactions with IgM antibodies against dengue, Japanese encephalitis and West 
Nile viruses could not be excluded [10]. These studies illustrate that cross-reactions between flaviviruses are 
common and results should be considered carefully. 
Event background information 
French Polynesia is a French overseas country that covers several groups of Polynesian islands: Marquesas Islands, 
Society  Islands  (Leeward  Islands  and  Windward  Islands),  Tuamotu,  Gambier  and  Austral  Islands.  The  overall 
population is 268 270 inhabitants (census 2012) living on 67 of the 118 islands spread over an area close to the 
size of continental Europe, but 75% of the population lives in the two main Islands, Tahiti and Moorea. The climate 
is tropical with a cool dry season (May to October) and warm rainy season (November to April) but with cooler 
climate  for  islands  in  the  southern  part.  The  average  annual  temperature  is  26°C,  ranging  from  a  minimum 
average of 21°C in August and a maximum average of 33°C in March. 
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Source: Central Intelligence Agency. World Fact Book. https://www.cia.gov/library/publications/the-world-
factbook/geos/fp.html 
Between October 2013 and 7 February 2014, 8 262 suspected cases of ZIKAV infection have been reported by the 
syndromic  surveillance  sentinel  network  of  French  Polynesia  [48].  The  effective  sentinel  network  during  the 
epidemic involved between 40 and 50 sentinel sites responding every week; 40% were private physicians and 60% 
public health centres and hospitals. Coverage is estimated at around 25% for the entire country, with sentinel sites 
localised on 25 islands from the five archipelagos. A suspected cases is defined as ‘an individual with maculo-
papular  erythematous  rash  and/or  fever  reported  measured  or  ≥38.5°  C  and  at  least  two  of  the  following 
symptoms and signs: i) conjunctival hyperemia (red eyes), ii) arthralgia and/or myalgia, and iii) oedema of the 
hands and/or feet’ [48]. 
As of 7 February 2014, of 746 samples sent for laboratory confirmation, 396 (53.1%) were confirmed by RT-PCR at 
Institut  Louis  Malardé.  It  is  estimated  that  more  than  28 000  cases  have  sought  medical  care  with  Zika-like 
symptoms in French Polynesia since the beginning of the outbreak (around 11.5% of the population of French 
Polynesia). The clinical presentation of confirmed Zika cases was consistent with the literature: mild fever, rash, 
non-purulent  conjunctivitis,  arthralgia,  myalgia,  headache  and  distal  oedema.  None  of  these  mild  cases  was 
hospitalised. 
According to Polynesia Epibulletin, 70 cases presented with neurological or auto-immune complications between 
November 2013 and 7 February 2014 [48]. 
Among those, there were 38 cases of Guillain–Barré syndrome (GBS) after the initial ZIKAV infection and 25 had 
neurological complications (encephalitis, meningo-encephalitis, paraesthesia, facial paralysis and myelitis). Seven 
cases  had  other  complications:  four  with  immune  thrombocytopenic  purpura,  two  were  ophthalmologic 
complications and one had a cardiac complication. 
Among the GBS cases, 73% were male, the mean age was 45.9 years (range: 27–70), and almost all cases were 
ethnic Polynesians. Fifteen cases were admitted to the intensive care unit and nine cases required mechanical 
ventilation. No deaths have been reported. All GBS cases developed neurological symptoms following a disease 
episode with symptoms compatible with ZIKAV infection in previous days, one of the cases has been laboratory-
confirmed to be Zika by RT-PCR at the initial infection, and other preliminary results show positive IgG against 
ZIKAV for several cases, after the occurrence of neurological signs [48].  
The clustering in time of GBS cases is considered unusual as the annual number of GBS cases in French Polynesia 
are 5, 10, 3 and 3 in 2009, 2010, 2011 and 2012, respectively. 
As of 31 January 2014, five patients remained hospitalised and overall a total of 18 individuals had been admitted 
to the local rehabilitation centre. The intensive care resources in this insular setting have been under intense stress 
to cope with patients presenting neurological complications. 
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Figure 1. Distribution of suspected Zika infection cases notified by sentinel network by week of 
reporting, as of week 04/2014 
 
Figure 2. Distribution of suspected Zika infection cases presenting with neurological and auto-
immunes complications notified by sentinel network by week of reporting and, as of week 04/2014 
 
Source: Adapted from [48,49] 
Figure  1  presents  the  distribution  of  suspected  cases  of  Zika  infection  from  the  sentinel  network  of  French 
Polynesia (n=8 039) and cases presenting with neurological or auto-immune complications, by week of reporting, 
as of week 4 of 2014. It should be considered that winter vacations (week 51 2013 to week 2 2014) might have 
decreased the number of respondents contributing to the sentinel surveillance system. 
The  association  between  auto-immune  neurological  and  haematological  complications  with  primary  and/or 
secondary co-infection with others flaviruses are under investigation. 
Co-infection with dengue virus is a possibility because of an outbreak of dengue virus type 1 and type 3 that has 
been ongoing since February 2013 in French Polynesia. According to the latest epidemiological bulletin, between 
12 400 and 25 700 suspected dengue cases, defined as dengue-like syndrome without laboratory confirmation, 
arose since February 2013 [48,49]. As of 7 February 2014, 1 656 cases of dengue infection had been laboratory-
confirmed. The majority of confirmed cases were notified in Tahiti and Moorea where most of the population 
resides,  and  sporadic  cases  were  reported  from  the  Marquises  and  Austral  islands  as  of  7  February  2014. 
Surveillance data indicate that the outbreak is now declining. 
In  the  Pacific  region,  ‘acute  fever  and  rash’  is  one  of  the  five  syndromes  (together  with  ‘dengue-like  illness’, 
influenza-like  illness’,  ‘diarrhoea’  and  ‘prolonged  fever’)  under  weekly  surveillance  by  the  Pacific  Public  Health 
Surveillance Network (PPHSN). In addition, the Pacific Syndromic Surveillance System is one of the five service 
networks  of  the  PPHSN.  The  22  Pacific  islands  Countries  and  Territories  (plus  New  Zealand)  have  been  
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participating in this surveillance system since 2010. Due to the risk of ZIKAV infection spreading in the region, 
surveillance  has  been enhanced  and  passengers  arriving  from French  Polynesia  in  New  Caledonia have  been 
screened since 2 November 2013 [50]. 
On 10 February 2014, health authorities in New Caledonia reported 64 cases; 30 of which were imported from 
French Polynesia and 34 were autochthonous infections with ZIKAV in the communities of Dumbea (14 cases), 
Ouvea (one case) and in Greater Nouméa (19 cases) [51,52]. Two travellers returning from French Polynesia to 
Japan were recently reported with Zika infection [11].  
In-depth  molecular  analyses  are  ongoing  to  determine  the  lineage and  clusters of  the Zika  viruses  in  French 
Polynesia. As the ZIKAV circulation in 2013 is reported in southern Asia and since the connection between the 
Pacific Islands and South-east Asia is noticeable, it is likely that the current strain belongs to the Asian lineage. 
Preliminary analysis of the partial ZIKAV E-protein genome sequence (470 bp) from one imported case to Japan 
shows a 99.1% sequence homology with ZIKAV strain isolated from Cambodia in 2010 and a 97.9% sequence 
homology with the sequence of a ZIKAV strain isolated on Yap island in 2007 [4, 28]. Additional epidemiological 
studies,  notably  a  case–control  study  in  French  Polynesia  and  a  prospective  survey  in  anticipation  of  a  new 
outbreak, should investigate the relation between ZIKAV infection and the occurrence of neurological and auto-
immune complication. Additional investigations are needed to better describe epidemiological and transmission 
characteristics and mechanisms (possibility of congenital infection or transmission through blood transfusion or 
other modes as reported in Foy), establish viral stain genetic characteristics, its pathogenicity and therefore its 
implications for public health [8].  
It is important to note that the Zika outbreak occurred in the context of concurrent circulation of two dengue 
serotypes, DEN 1 (predominantly) and DEN 3, since February 2013. Prior to 2013, dengue virus serotype 3 (DENV-
3) had not been identified in the Pacific island nations for almost 20 years. Meanwhile neurological and auto-
immune  complications  have  been  reported  during  outbreaks  of  different  flaviviruses  but  are  not  frequent  for 
dengue, and more important for viruses with neurological tropism such as West Nile [53-58]. One case of Guillain–
Barré syndrome following DEN 4 infection has been reported in French Polynesia in the literature [59]. Specific 
studies including genetic investigation would provide additional information to further assess the unusual clinical 
patterns described during this Zika outbreak. 
In  conclusion,  outbreaks  of  ZIKAV  infection  on  Yap  Island  (2007)  and  in  French  Polynesia  have  shown  the 
propensity of this arbovirus to spread outside its usual geographical range and its capacity to cause large-scale 
outbreaks. 
ECDC threat assessment for the EU 
French Polynesia is affected by a Zika outbreak representing a risk that the disease will spread further in the Pacific 
region as the competent vectors are widely present, notably in New Caledonia, where imported cases and recently 
autochthonous cases have been notified. 
The knowledge on the epidemiology of Zika is limited as it is an emerging pathogen, so significant outbreaks need 
to be carefully investigated to better assess the risk of spread and its consequences for public health. 
Risk for the continental EU 
Although geographically far from continental Europe, overseas territories of Oceania have close connections with 
the EU. Therefore, travel-related cases of Zika returning from French Polynesia or from New Caledonia, depending 
on the evolution of the outbreak, can be expected. Since a possible association with neurological and auto-immune 
complications has been reported, such as GBS generally occurring at a period after the primary infectious episode, 
sporadic  neurological  complications  for  travel-related  cases  might  be  expected.  Therefore,  vigilance  must  be 
enhanced regarding imported cases in the EU Member States, including awareness among clinicians and travel 
clinics, notably of febrile cases not attributable to dengue and chikungunya infections.  
The EU has laboratory capacity to detect ZIKAV. On 7 February 2014, 20 laboratories of the European Network of 
Viral lmported Diseases (ENIVD) from 13 EU countries have the capacity to detect ZIKAV genome (11 laboratories 
use a ZIKAV-specific PCR assay and nine laboratories use a generic pan-flavivirus PCR assay and sequencing). Five 
laboratories already received ZIKA investigation requests. The network provides a standard ZIKAV preparation for 
PCR diagnostic purpose on request (www.enivd.org). 
Viraemic asymptomatic returning travellers could contribute to transmission of the disease if giving blood. Blood 
safety authorities therefore need to be attentive to the epidemiological situation and should consider deferral of 
donors with travel history in line with measures defined for West Nile virus, i.e. a deferral period of 28 days after 
leaving an area with ongoing transmission of ZIKAV to humans [60]. 
Onward transmission from imported cases to the continental EU is not expected during the winter season because 
of the low activity of the vector but could occur during the summer months in areas where Aedes aegypti is 
established. Aedes albopictus is well established in many parts of the EU, primarily around the Mediterranean. The 
risk of onward autochthonous transmission of ZIKAV during the mosquito season cannot be excluded given the fact  
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that Aedes albopictus is identified as a potential competent vector [24,40]. The capacity of European populations 
of Aedes albopictus to transmit ZIKAV would need to be assessed. 
Risk for EU overseas countries and territories and outermost 
regions 
An outbreak of ZIKAV infection has been ongoing in French Polynesia since the beginning of October 2013. The 
risk of the disease spreading from French Polynesia to other islands in the Pacific region is high. The spread would 
most likely result from viraemic individuals travelling to areas with competent vectors, as illustrated recently in New 
Caledonia. The risk for onward transmission is likely because of the widespread distribution of the vectors. 
Likewise, outside the Pacific region, the spread to EU overseas countries and territories and outermost regions is 
conceivable with a risk of onward transmission due to the presence of the competent vectors. Therefore, high 
vigilance must be ensured regarding imported cases in EU overseas countries and territories and outermost regions 
including awareness among clinicians and travel clinics, notably to febrile cases not attributable to dengue and 
chikungunya infections. 
Conclusions and options for mitigation 
  This is the first documented outbreak of ZIKAV infection in French Polynesia and New Caledonia. 
  During the course of the ZIKAV outbreak, neurological and auto-immune complications have been reported 
in a context of concurrent circulation of two dengue serotypes (dengue 1 and 3) since February 2013. 
  Vigilance must be enhanced towards imported cases of ZIKAV infection in the EU Member States and EU 
overseas countries and territories and outermost regions, in particular where effective vectors are present; 
early detection of cases is essential to reduce the risk of autochthonous transmission. 
  Clinicians and travel medicine clinics should be aware of the situation in the Pacific islands and include 
ZIKAV infection in their differential diagnosis. An isolated positive result for dengue IgM antibodies among 
travellers returning from areas affected by Zika should prompt a possible investigation for another flavivirus 
aetiology.  
  The potential neurological and auto-immune complications might require specific healthcare capabilities and 
treatment (ICU) which need to be taken into account in an insular context facing a large-scale Zika 
outbreak.  
  As an emerging pathogen, the laboratory capacity to confirm suspected Zika cases should be strengthened 
in the region as well as in Europe to differentiate ZIKAV infections from other arboviral dengue-like 
illnesses. Regional reference laboratories could provide support to confirm suspect cases.  
  As many unanswered questions remain, further epidemiological and laboratory investigations could be 
conducted to establish: 
−  evidence about eco-epidemiology of ZIKAV (viral strain genetic characteristics, transmission cycle(s), 
vectors and reservoir hosts) to assess its implications for public health; 
−  the relationship between neurological and auto-immune complications and ZIKAV infection, notably 
with other aetiologies, previous infection with other infectious agents and human risk factors;  
−  the performance of Zika serology and its cross-reactivity with other flaviviral infections; 
−  the possibility of using urine samples for detection of ZIKAV genome as well as other flaviviral 
infections.  
  Blood safety authorities need to be vigilant regarding the epidemiological situation and should consider 
deferral of donors with travel history in line with measures defined for West Nile virus. Blood safety 
procedures are already in place in the Pacific region in the context of the ongoing outbreak of dengue and 
chikungunya and have included ZIKAV nucleic acid testing since early January 2014 in French Polynesia.  
  As exposure to infected mosquitoes is likely to be the principal risk for infection, prevention of ZIKAV 
infection is based on protection against mosquito bites and vector control; these have to be customised 
according to the potential vector species actually present in the area. 
  Onward transmission in the EU from imported cases during the winter season is not to be expected, but 
vigilance during the mosquito season is required in areas where a potential vector is present. Indeed the 
possibility of autochthonous transmission of tropical mosquito-transmitted viruses in continental Europe 
does exist. 
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